PMID- 37614237
OWN - NLM
STAT- MEDLINE
DCOM- 20230830
LR  - 20230831
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as 
      second or later-line treatment for patients with advanced non-small-cell lung 
      cancer: a systematic review and single-arm meta-analysis of prospective clinical 
      trials.
PG  - 1218258
LID - 10.3389/fimmu.2023.1218258 [doi]
LID - 1218258
AB  - BACKGROUND: Previous studies revealed that Programmed cell death protein 1 
      (PD-1)/Programmed cell death-Ligand protein 1 (PD-L1) inhibitors plus 
      anti-angiogenic agents had extensive anti-tumor activities. However, almost all 
      studies on the efficacy and safety of PD-1/PD-L1 inhibitors plus anti-angiogenic 
      agents as second or later-line treatment for patients with advanced non-small 
      cell lung cancer are non-randomized controlled trials with small sample sizes, 
      which might lead to a lack of effective metrics to assess the effectiveness and 
      safety of the therapeutic regimen. Here, this meta-analysis aimed to evaluate the 
      efficacy and safety of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as 
      second or later-line treatment for patients with advanced non-small cell lung 
      cancer. METHODS: A single-arm meta-analysis was performed, and published 
      literature from PubMed, Web of Science and Embase databases as of January 13, 
      2023, was systematically retrieved. We used the Cochrane risk of bias tool and 
      methodological index for non-randomized studies (MINORS) Methodological items to 
      evaluate the quality of eligible clinical trials. Outcomes including overall 
      response rate (ORR), disease control rate (DCR), progression-free survival (PFS), 
      overall survival (OS), and adverse events (AEs) were extracted for further 
      analysis. The random effect model is used to calculate the pooled parameters. 
      RESULTS: 19 studies (16 were non-comparative single-arm clinical trials and 3 
      were randomized controlled trials) were enrolled in this meta-analysis. In terms 
      of tumor response, the pooled ORR and DCR were 22.4% (95% CI, 16.6-28.1%) and 
      76.8% (95% CI, 72.6-81.1%), respectively. With regard to survival analysis, the 
      pooled PFS and OS were 5.20 (95% CI, 4.46-5.93) months and 14.09 (95% CI, 
      13.20-14.97) months, respectively. The pooled grade >/=3 adverse effect (AE) rate 
      was 47.6% (95% CI, 33.1-62.0%). CONCLUSION: PD-1/PD-L1 inhibitors plus 
      anti-angiogenic agents has promising efficacy and safety as second or later-line 
      treatment in patients with advanced non-small cell lung cancer. SYSTEMATIC REVIEW 
      REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42023407559.
CI  - Copyright (c) 2023 Chen, Mo, Jiang, Zhou, Gan and Yu.
FAU - Chen, Shubin
AU  - Chen S
AD  - Medical Oncology Of Respiratory, Guangxi Medical University Cancer Hospital, 
      Nanning, Guangxi, China.
FAU - Mo, Wanying
AU  - Mo W
AD  - Medical Oncology Of Respiratory, Guangxi Medical University Cancer Hospital, 
      Nanning, Guangxi, China.
FAU - Jiang, Wei
AU  - Jiang W
AD  - Medical Oncology Of Respiratory, Guangxi Medical University Cancer Hospital, 
      Nanning, Guangxi, China.
FAU - Zhou, Shaozhang
AU  - Zhou S
AD  - Medical Oncology Of Respiratory, Guangxi Medical University Cancer Hospital, 
      Nanning, Guangxi, China.
FAU - Gan, Haijie
AU  - Gan H
AD  - Medical Oncology Of Respiratory, Guangxi Medical University Cancer Hospital, 
      Nanning, Guangxi, China.
FAU - Yu, Qitao
AU  - Yu Q
AD  - Medical Oncology Of Respiratory, Guangxi Medical University Cancer Hospital, 
      Nanning, Guangxi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230808
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Humans
MH  - Angiogenesis Inhibitors/adverse effects
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - *Lung Neoplasms/drug therapy
MH  - Programmed Cell Death 1 Receptor
MH  - Prospective Studies
MH  - Clinical Trials as Topic
PMC - PMC10442655
OTO - NOTNLM
OT  - PD-1/PD-L1 inhibitors
OT  - advanced non-small cell lung cancer
OT  - anti-angiogenic agents
OT  - meta-analysis
OT  - second or later-line therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/24 06:42
MHDA- 2023/08/25 06:42
PMCR- 2023/01/01
CRDT- 2023/08/24 03:55
PHST- 2023/05/06 00:00 [received]
PHST- 2023/07/24 00:00 [accepted]
PHST- 2023/08/25 06:42 [medline]
PHST- 2023/08/24 06:42 [pubmed]
PHST- 2023/08/24 03:55 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1218258 [doi]
PST - epublish
SO  - Front Immunol. 2023 Aug 8;14:1218258. doi: 10.3389/fimmu.2023.1218258. 
      eCollection 2023.